OHSU - Health Care - Division of Hematology and Medical Oncology

Our Faculty

David Qian, Ph.D.
Assistant Professor

Phone: 503-494-4393
E-mail: qianzh@ohsu.edu

Research Focus

Molecular & cellular mechanism of chemotherapy stress response and resistance.
The epigenetics of HIF-1 and mitochondria biogenesis.
Targeting prostate cancer and angiogenesis with HDAC inhibitors.

Appointments Assistant Professor - School of Medicine, Department of Medicine, Division of Hematology & Medical Oncology		Professional Education and Training 2002 - Doctor of Philosophy (Ph.D.) in Toxicology & Molecular Epidemiology, Johns Hopkins University, Bloomberg School of Public Health 1994 - Bachelor of Science (BS) in Biochemistry, Alma College
Personal		Professional Experience 2007 - current, Assistant Professor, Prostate Program, Division of Hematology & Medical Oncology, Department of Medicine, School of Medicine, Oregon Health & Science University 2006-2007, Research Associate, Dr. Gregg Semenza Lab, Program of Vascular Biology, Institute of Cell Engineering, Johns Hopkins School of Medicine 2002-2006, Post-Doctoral Fellow, Dr. Roberto Pili Lab, Johns Hopkins Kimmel Cancer Center & Johns Hopkins School of Medicine

Selected Publications

Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Inaugural Article: Digoxin and other cardiac glycosides inhibit HIF-1{alpha} synthesis and block tumor growth. Proc Natl Acad Sci U S A. 2008 Nov 19.

Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007 Sep 15;13: 5341-7.

Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate. 2007 Aug 1;67(11):1182-93.

Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006 Jan 15;12(2):634-42.

Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006 Sep 1;66(17):8814-21.

Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate. 2005 Jun 15;64(1):20-8.

Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004 Sep 15;64(18):6626-34.